1
|
Kim WT, Kim K, Kang HW, Byun YJ, Piao XM, Kim YJ, Lee SC, Yun SJ, Ha YS, Kim J, Kim IY. Single‑center, retrospective, evaluator‑blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2‑miR‑H9/hsa‑miR‑3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zone. Oncol Lett 2025; 29:23. [PMID: 39512501 PMCID: PMC11542165 DOI: 10.3892/ol.2024.14770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2024] [Accepted: 09/19/2024] [Indexed: 11/15/2024] Open
Abstract
Prostate-specific antigen (PSA) remains a key biomarker for the diagnosis and monitoring of prostate cancer (PCa). For patients within the 'PSA gray zone', the positive predictive value (PPV) of PSA for PCa detection by biopsy is estimated to be between 30 and 42%. In the present study, a single-center, retrospective, evaluator-blinded, pilot and pivotal clinical trial was performed to assess the clinical performance of the mirCaP kit (Urotech, Inc.), which measures the herpes simplex virus 2-microRNA (miR)-H9/hsa-miR-3659 ratio, with respect to helping physicians make appropriate decisions regarding further assessment of patients with PSA levels within this gray zone. For the patients in the initial clinical trial group who were in the PSA gray zone, the sensitivity, specificity, accuracy, PPV and negative predictive value (NPV) of the mirCaP kit were 94.29, 77.50, 85.33, 78.57 and 93.94%, respectively. For those in the pivotal clinical trial, these values were 94.50, 82.73, 87.90, 81.10 and 95.04%, respectively. These results suggest that the mirCaP kit may be an effective non-invasive diagnostic marker for PCa in patients with PSA levels in the gray zone. Thus, the mirCaP kit is a promising tool that can help physicians make a decision regarding the need for prostate biopsy in these patients. Of note, the NPV of >90% indicates that the mirCaP kit could prevent unnecessary prostate biopsies in >90% of these cases.
Collapse
Affiliation(s)
- Won Tae Kim
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea
- Department of Urology, Chungbuk National University Hospital, Cheongju, Chungbuk 28644, Republic of Korea
| | - Kyeong Kim
- Department of Urology, Chungbuk National University Hospital, Cheongju, Chungbuk 28644, Republic of Korea
| | - Ho Won Kang
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea
- Department of Urology, Chungbuk National University Hospital, Cheongju, Chungbuk 28644, Republic of Korea
| | - Young Joon Byun
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea
| | - Xuan-Mei Piao
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea
| | - Yong-June Kim
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea
- Department of Urology, Chungbuk National University Hospital, Cheongju, Chungbuk 28644, Republic of Korea
| | - Sang Cheol Lee
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea
- Department of Urology, Chungbuk National University Hospital, Cheongju, Chungbuk 28644, Republic of Korea
| | - Seok Joong Yun
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea
- Department of Urology, Chungbuk National University Hospital, Cheongju, Chungbuk 28644, Republic of Korea
| | - Yun-Sok Ha
- Department of Urology, School of Medicine, Kyungpook National University, Daegu, North Gyeongsang 41404, Republic of Korea
| | - Jiyeon Kim
- Department of Urology, Yale School of Medicine, New Haven, CT 06510, USA
| | - Isaac Yi Kim
- Department of Urology, Yale School of Medicine, New Haven, CT 06510, USA
| |
Collapse
|
2
|
Lee YS, Ha MS, Tae JH, Chang IH, Kim TH, Myung SC, Nguyen TT, Kim M, Lee KE, Kim Y, Woo HK, Kyoung DS, Kim H, Choi SY. Gemcitabine-cisplatin versus MVAC chemotherapy for urothelial carcinoma: a nationwide cohort study. Sci Rep 2023; 13:3682. [PMID: 36879015 PMCID: PMC9988935 DOI: 10.1038/s41598-023-30356-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Accepted: 02/21/2023] [Indexed: 03/08/2023] Open
Abstract
This study assessed the trends in methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) and gemcitabine-cisplatin (GC) regimens in Korean patients with metastatic urothelial carcinoma (UC) and compared the side effects and overall survival (OS) rates of the two regimens using nationwide population-based data. The data of patients diagnosed with UC between 2004 and 2016 were collected using the National Health Insurance Service database. The overall treatment trends were assessed according to the chemotherapy regimens. The MVAC and GC groups were matched by propensity scores. Cox proportional hazard analysis and Kaplan-Meier analysis were performed to assess survival. Of 3108 patients with UC, 2,880 patients were treated with GC and 228 (7.3%) were treated with MVAC. The transfusion rate and volume were similar in both the groups, but the granulocyte colony-stimulating factor (G-CSF) usage rate and number were higher in the MVAC group than in the GC group. Both groups had similar OS. Multivariate analysis revealed that the chemotherapy regimen was not a significant factor for OS. Subgroup analysis revealed that a period of ≥ 3 months from diagnosis to systemic therapy enhanced the prognostic effects of the GC regimen. The GC regimen was widely used as the first-line chemotherapy in more than 90% of our study population with metastatic UC. The MVAC regimen showed similar OS to the GC regimen but needed greater use of G-CSF. The GC regimen could be a suitable treatment option for metastatic UC after ≥ 3 months from diagnosis.
Collapse
Affiliation(s)
- Yong Seong Lee
- Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gyeonggi-Do, Republic of Korea
| | - Moon Soo Ha
- Department of Urology, Hyundae General Hospital, Chung-Ang University College of Medicine, Gyeonggi-Do, Republic of Korea
| | - Jong Hyun Tae
- Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-Ro, Dongjak-Gu, Seoul, 06973, Republic of Korea
| | - In Ho Chang
- Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-Ro, Dongjak-Gu, Seoul, 06973, Republic of Korea
| | - Tae-Hyoung Kim
- Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-Ro, Dongjak-Gu, Seoul, 06973, Republic of Korea
| | - Soon Chul Myung
- Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-Ro, Dongjak-Gu, Seoul, 06973, Republic of Korea
| | - Tuan Thanh Nguyen
- Department of Urology, Cho Ray Hospital, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
| | - Myoungsuk Kim
- Data Science Team, Evidnet. Co., Ltd, Seoul, Republic of Korea
| | - Kyung-Eun Lee
- Data Science Team, Evidnet. Co., Ltd, Seoul, Republic of Korea
| | - Yuwon Kim
- Data Science Team, Evidnet. Co., Ltd, Seoul, Republic of Korea
| | - Hyun-Ki Woo
- Data Science Team, Evidnet. Co., Ltd, Seoul, Republic of Korea
| | - Dae-Sung Kyoung
- Data Science Team, Hanmi Pharm. Co., Ltd, Seoul, Republic of Korea
| | - Hasung Kim
- Data Science Team, Hanmi Pharm. Co., Ltd, Seoul, Republic of Korea
| | - Se Young Choi
- Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-Ro, Dongjak-Gu, Seoul, 06973, Republic of Korea.
| |
Collapse
|
3
|
Kim SS, Lee SC, Lim B, Shin SH, Kim MY, Kim SY, Lim H, Charton C, Shin D, Moon HW, Kim J, Park D, Park WY, Lee JY. DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia. Prostate Int 2023. [DOI: 10.1016/j.prnil.2023.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
|
4
|
Bergez-Hernández F, Arámbula-Meraz E, Alvarez-Arrazola M, Irigoyen-Arredondo M, Luque-Ortega F, Martínez-Camberos A, Cedano-Prieto D, Contreras-Gutiérrez J, Martínez-Valenzuela C, García-Magallanes N. Expression Analysis of miRNAs and Their Potential Role as Biomarkers for Prostate Cancer Detection. Am J Mens Health 2022; 16:15579883221120989. [PMID: 36082407 PMCID: PMC9465588 DOI: 10.1177/15579883221120989] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Prostate cancer (PCa) is the second most frequent cancer diagnosed in men worldwide. The detection methods for PCa are either unreliable, like prostate-specific antigen (PSA), or extremely invasive, such as in the case of biopsies. Therefore, there is an urgent necessity for reliable and less invasive detection procedures that can differentiate between patients with benign diseases and those with cancer. In this matter, microRNAs (miRNAs) are suggested as potential biomarkers for cancer. MiRNAs have been found to be dysregulated in several different cancers, and these genetic alterations may present specific signatures for a given malignancy. Here, we examined the expression of miR141-3p, miR145-5p, miR146a-5p, and miR148b-3p in human tissue samples of PCa (n = 41) and benign prostatic diseases (BPD) (n = 30) using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). We combined the expression results with patient clinicopathological characteristics in logistic regression models to create accurate PCa predictive models. A model including information of miR148b-3p and patient age showed relevant prediction results (area under the curve [AUC] = 0.818, precision = 0.763, specificity = 0.762, and accuracy = 0.762). A model including all four miRNAs and patient age presented outstanding prediction results (AUC = 0.918, precision = 0.861, specificity = 0.861, and accuracy = 0.857). Our results represent a potential novel procedure based on logistic regression models that utilize miRNA expressions and patient age to assist with PCa diagnosis.
Collapse
Affiliation(s)
- Fernando Bergez-Hernández
- Posgrado en Ciencias Biomédicas,
Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Sinaloa,
Culiacán Rosales, México
| | - Eliakym Arámbula-Meraz
- Laboratorio de Genética y
Biología Molecular, Facultad de Ciencias Químico Biológicas, Universidad
Autónoma de Sinaloa, Culiacán Rosales, México
| | | | - Martín Irigoyen-Arredondo
- Posgrado en Ciencias Biomédicas,
Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Sinaloa,
Culiacán Rosales, México
| | - Fred Luque-Ortega
- Laboratorio de Ciencias Básicas,
Facultad de Odontología, Universidad Autónoma de Sinaloa, Culiacán Rosales,
México
| | - Alejandra Martínez-Camberos
- Posgrado en Ciencias Biomédicas,
Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Sinaloa,
Culiacán Rosales, México
| | - Dora Cedano-Prieto
- Laboratorio de Genética y
Biología Molecular, Facultad de Ciencias Químico Biológicas, Universidad
Autónoma de Sinaloa, Culiacán Rosales, México
| | - José Contreras-Gutiérrez
- Centro de Investigación y
Docencia en Ciencias de la Salud, Hospital Civil de Culiacán, Universidad
Autónoma de Sinaloa, Culiacán Rosales, México
| | - Carmen Martínez-Valenzuela
- Laboratorio de Genotoxicología
“Dr Jesus Kumate Rodriguez,” Unidad de Investigación en Ambiente y Salud,
Universidad Autónoma de Occidente, Los Mochis, México
| | - Noemí García-Magallanes
- Laboratorio de Biomedicina y
Biología Molecular, Ingeniería en Biotecnología, Universidad Politécnica de
Sinaloa, Mazatlán, México,Noemí García Magallanes,
Laboratorio de Biomedicina y Biología Molecular, Ingeniería en
Biotecnología, Universidad Politécnica de Sinaloa, Carretera Municipal
Libre Mazatlán-Higueras s/n 3km col. Genaro Estrada, 82199 Mazatlán,
Sinaloa, México.
| |
Collapse
|
5
|
Kim K, Youm JY, Lee EH, Gulenko O, Kim M, Yoon BH, Jeon M, Kim TH, Ha YS, Yang JM. Tapered catheter-based transurethral photoacoustic and ultrasonic endoscopy of the urinary system. OPTICS EXPRESS 2022; 30:26169-26181. [PMID: 36236812 DOI: 10.1364/oe.461855] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2022] [Accepted: 06/13/2022] [Indexed: 06/16/2023]
Abstract
Early diagnosis is critical for treating bladder cancer, as this cancer is very aggressive and lethal if detected too late. To address this important clinical issue, a photoacoustic tomography (PAT)-based transabdominal imaging approach was suggested in previous reports, in which its in vivo feasibility was also demonstrated based on a small animal model. However, successful translation of this approach to real clinical settings would be challenging because the human bladder is located at a depth that far exceeds the typical penetration depth of PAT (∼3 cm for in vivo cases). In this study, we developed a tapered catheter-based, transurethral photoacoustic and ultrasonic endoscopic probe with a 2.8 mm outer diameter to investigate whether the well-known benefits of PAT can be harnessed to resolve unmet urological issues, including early diagnosis of bladder cancer. To demonstrate the in vivo imaging capability of the proposed imaging probe, we performed a rabbit model-based urinary system imaging experiment and acquired a 3D microvasculature map distributed in the wall of the urinary system, which is a first in PAT, to the best of our knowledge. We believe that the results strongly support the use of this transurethral imaging approach as a feasible strategy for addressing urological diagnosis issues.
Collapse
|